Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Omalizumab

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Penalver de la Puente E, et al. Biological drug therapy in allergic bronchopulmonary aspergillosis without cystic fibrosis. Description of 4 cases with omalizumab and 1 case with mepolizumab after switching from omalizumab. Allergy 78 (Suppl. 111): 631 (plus poster) abstr. 001694, Feb 2023. Available from: URL: https://onlinelibrary.wiley.com/doi/10.1111/all.15616 [abstract] Penalver de la Puente E, et al. Biological drug therapy in allergic bronchopulmonary aspergillosis without cystic fibrosis. Description of 4 cases with omalizumab and 1 case with mepolizumab after switching from omalizumab. Allergy 78 (Suppl. 111): 631 (plus poster) abstr. 001694, Feb 2023. Available from: URL: https://​onlinelibrary.​wiley.​com/​doi/​10.​1111/​all.​15616 [abstract]
Metadaten
Titel
Omalizumab
Lack of efficacy: case report
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-39023-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Elasomeran

Case report

Elasomeran

Case report

Imatinib

Case report

Aumolertinib